Stories

A decade ago, medicine development looked very different. Today, some of the most exciting science is coming from small, focused teams moving at speed – teams working under real operational constraints, with little room for anything that slows them down. 

For a company like Ipsen, environmental impact doesn’t stop at the boundaries of its operations. In fact, that’s only a small part of the picture.

In biopharmaceutical research, not all challenges are equal. Some of the most meaningful opportunities lie in areas defined by complex biology, limited evidence, and patients who have waited far too long for effective treatment options.  

In today’s rapidly evolving treatment landscape the approval of a medicine is no longer the finish line; it’s just the beginning. Real world evidence (RWE), post-hoc analyses and structured Phase IV studies all offer new opportunities for scientific learning. At Ipsen, we’re committed to pursuing the unanswered questions, generating robust evidence that goes beyond medicine development, which provides broader long-term evidence-based perspectives for the communities we serve. 

A diagnosis is supposed to be the end of the uncertainty. For some families, it is also the moment they realize there is nothing more medicine can offer. Loubna Ouriaghli, Head of Government Affairs & Policy at Ipsen, witnessed that moment with her own mother who was diagnosed with a rare disease.  She saw the symptoms appear one by one, the years it took to finally have an answer and the silence that followed when that answer came with no treatment. 

We’re excited to be at the European Association for the Study of the Liver (EASL) Congress 2026, Europe’s largest event dedicated to liver health where doctors, scientists, allied health professionals, patients, and industry partners come together to share knowledge, highlight scientific breakthroughs, and build meaningful connections.

There are moments that stay with you. Not because of a single slide or headline, but because you can feel something changing. Expectations shift. Standards rise. A new chapter begins. 

Ipsen’s 2025 Integrated Annual report report is now available on Ipsen.com. This essential reference document brings together key information and insights into the major developments in 2025 and what lies ahead.

“All medicines have side effects, but it’s just about trying to minimize the impact through providing the information patients and clinicians need or finding other ways to mitigate that impact.” — Jacintha Sivarajah 

Ipsen is not new to aesthetics. For more than three decades, we have been advancing neuroscience innovations across therapeutic and aesthetic indications, building deep expertise in complex biologics, rigorous clinical development and high‑quality manufacturing.

Ipsen reports 22.6% sales growth at constant exchange rates in Q1 2026, reflecting balanced growth across Oncology, Rare Disease, and Neuroscience.

For the hundreds of children diagnosed with pediatric low-grade glioma (pLGG) across Europe each year, the journey is rarely what families expect. It is often long, complex, and life-altering. However today, we’re excited that the treatment landscape has progressed.  

In the pharmaceutical industry, it’s easy to focus on data, strategy, and performance metrics. But behind every decision are real people. For Guillermo Castillo Acero, Head of European Mid-Sized Markets at Ipsen, that reality became clear during a precise moment in his career.

For too long, modern medicine has treated diseases as if they were uniform, defined by a label rather than by their underlying biology. Today, we have an unprecedented ability to interrogate the molecular drivers that shape each person’s cancer, and in doing so, we’re transforming how we diagnose, develop and deliver the medicines that matter most.

At the heart of Ipsen’s early discovery efforts is a question of fit—how a molecule interacts with a disease-relevant protein, and what that means for therapeutic potential. Alexis Cocozaki’s team focuses on that exact space, applying biophysical and structural biology techniques to evaluate and optimize new assets at the atomic level. 

We are pleased to announce that Ipsen’s 2025 Sustainability Statement – our annual publication outlining Ipsen’s environmental, social and governance (ESG) commitments, progress and priorities – is now available on our website, reflecting our commitment to maximize positive change for future generations.

Working in early development, I have the privilege to see the next generation of therapeutic science take shape – and few areas are more compelling than immuno-oncology (I-O). From first data points in the lab to breakthroughs in the clinic, it is clear that we are entering a new era with the potential to deliver transformative outcomes for patients.

Late-stage partnering is unforgiving — high-stakes, capital-intensive, and fiercely competitive. The cost of a poor partnership isn’t just financial; it’s the lost opportunity to advance a program that could have changed patient outcomes but didn’t get the right partner at the right moment.

For many people at Ipsen, the impact of their work becomes clear through patient stories, scientific breakthroughs, or moments shared with colleagues. For Emilie Manier, Senior Executive Assistant, that realization came in a much more unexpected situation: a dinner with friends. 

New in our A Life in Science series, we hear from Audrey Clapéron, Translational Biology Director, about the essential role of data in driving discovery forward. She shares how leading a team of pharmacologists and delivering high-quality evidence for clinical development keeps her motivated and close to the patients who may one day benefit.

The science behind cell culture and fermentation rarely makes headlines. But without it, no treatment would reach a patient. Alison Mason knows this better than most.

New in our A Life in Science series, we hear from Mary Jane Hinrichs, Senior Vice President and Head of Early Development, about her path from discovering a passion for pharmacology to leading drug candidates through first-in-human trials. She shares how balancing strategy, science, and a constant focus on patients motivates her to shape the future of medicines.

A replay with complete presentation and Q&A session will be made available soon after the Annual General Meeting.

New in our A Life in Science series, we hear from Elodie Lewkowicz, Asset Lead, about how curiosity and collaboration drive her mission to tackle the complexity of cancer. She reflects on mentoring, developing the next generation of scientists, and keeping patients at the heart of every data point to stay motivated through challenges.

The European Neuroendocrine Tumor Society (ENETS) 4 – 6 March 2026 conference in Kraków is one of the most important moments of the year for the global NET community. Clinicians, researchers, nurses, advocates and partners come together with a shared purpose to expand understanding of neuroendocrine tumors (NETs) and improve care for people living with them.

Every year, new breakthroughs reveal possibilities for treating conditions once thought untreatable. But possibility alone is not enough. The true challenge lies in identifying compelling scientific opportunities early—and shaping them deliberately so they can one day make a meaningful impact for patients. At Ipsen, we recognize the potential of early science; where bold ideas thrive and where there is the greatest risk but also the potential to change patients’ lives.

Rare Disease Day reminds us that rare conditions impact far more lives than many realize -over 300 million people globally, across more than 10,000 identified rare diseases. Yet what strikes me most on this day of recognition and reflection is that listening to patients remains an under-utilized lever for achieving progress in healthcare.

Each year, hundreds of children across Europe are diagnosed with pLGG. For many, the journey involves invasive surgeries, years of intensive chemotherapy and the lifelong impact of potential vision, speech and neurological complications. With no global standard of care, families are often left facing uncertainty, complexity and incredibly difficult choices often over many years.

In an era where breakthrough science increasingly depends on deep, cross sector collaboration, the longstanding partnership between Ipsen and the teams at the Institute for Research in Immunology and Cancer (IRIC) and its commercialization unit, IRICoR, at Université de Montréal stands out as a model for how academia and industry can accelerate science with purpose.

As the global GU oncology community prepares to gather in San Francisco for the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), colleagues from across Ipsen are energized by the opportunity to connect, learn, and contribute

Rare diseases are more common than most people imagine, in how many lives they touch and in how profoundly they shape everyday life for patients and families. Behind every diagnosis is a person navigating far more than symptoms: daily routines transformed, ambitions redefined, misunderstanding and isolation to navigate and families adapting to uncertainty with resilience and hope.

New in our A Life in Science series, we hear from Florence Meyer-Losic, Vice President and Head of Translational Sciences, about her journey from veterinary medicine to human research. She highlights the importance of adaptability, continuous learning, and diverse expertise in building successful teams that deliver innovative treatments for patients.

FY 2025 was a year of strong execution and robust performance across all therapeutic areas, driving significant topline growth and reinforcing the company’s strategic momentum. Total sales grew 10.9% at constant exchange rates (CER), supported by a solid 7.5% growth in Q4.

New in our A Life in Science series, we hear from Eli Leo, Early Development Asset Lead, about how teamwork, creativity, and even failure fuel progress in research. From seeing herself as a conductor guiding scientists like an orchestra to learning from the 98% of experiments that do not succeed, she shows how resilience and collaboration create meaningful breakthroughs for patients.

Before a medicine reaches patients, its promise must be measured against its risks. For Lineu Domit, safety physician in Ipsen’s Global Patient Safety team, this balance is the essence of early development.

As we prepare to mark World Cancer Day, which continues its three-year commitment to the powerful global theme of “United by Unique”, Ipsen acknowledges the immense, global challenge that cancer presents.

Together for the Climate: Ipsen Strengthens Its Climate Commitment with CDP A-List Recognition and SBTi Approval 

“We were shocked” That is how Celine felt when her family received the news that her daughter Suzanne had been diagnosed with the rare liver disease, Alagille Syndrome (ALGS) at just a few months old.

At Ipsen, our heritage in neuroscience has always been about more than advancing science – it is about transforming lives. Despite advances in care and numerous initiatives to prevent stroke, cases continue to rise over recent decades.

Elisabetta Leo is moving science forward at the heart of early development. This involves progressing nonclinical data and novel molecules in oncology, from bench to bedside.

Philippe Lopes-Fernandes, EVP & Chief Business Officer, shares how Ipsen’s tenacious approach to dealmaking is transforming breakthrough science into global impact—solidly.

Developing an antibody-drug conjugate (ADC) is a technical challenge. Across Ipsen’s work in ADCs Will Olughu leads a team driving the chemistry, manufacturing, and controls (CMC) effort to bring this complex science into reality.

It is a pivotal moment in Ipsen’s oncology journey, advancing our clinical-stage pipeline with bold science and a clear purpose – to bring meaningful innovation to the patients who need it most, transforming what patients and healthcare systems can expect from cancer treatment.

The future of biopharma will be shaped not by the biggest players, but by the most agile ones. That is why I believe our operating model at Ipsen gives us a real advantage in today’s fast-moving landscape.

This is My PBC is a disease awareness initiative developed and funded by Ipsen, that seeks to raise awareness of the need for people living with PBC to know more about their disease and understand that everyone’s experience is different – and valid. By taking a personalized approach to your PBC management, you can empower yourself with the knowledge to have meaningful conversations with your healthcare professional, and play a more active role in your PBC management and care. You may be unique, but you are not alone.

Jo’s journey to diagnosis began about 10 years ago, when she contacted her GP feeling tired and run down, but it wasn’t until 4 years ago following some routine blood tests and a liver biopsy, that she received a diagnosis. Support groups, like the PBC Foundation, have been a gamechanger for Jo, providing support, education and a like-minded community.

Wendy has been living with PBC for over 13 years, and it took 5 years of GP and specialist appointments to receive her diagnosis. Her advice to other people living with PBC is to go to your doctor prepared to ask lots of questions, manage your condition as well as you can and be kind to yourself.

Gill is a devoted mother and grandmother who loves spending time with her grandchildren and gardening. She also has a real passion for her volunteering work. She has lived for over 20 years with PBC.

Robustness is not a box to check—it’s the foundation of every decision. As a Senior Director in the Pharmaceutical Development function in Ipsen’s drug product development team, Prince Korah focuses on driving the pharmaceutical development strategy by overseeing the end-to-end life cycle of drug products with his team.

We’re proud to share that Ipsen has been certified as a Great Place to Work in 16 countries in 2025, bringing our total to 30 countries worldwide recognized as employers of choice. This achievement is a strong testament to our…

At Ipsen, we go beyond environmental responsibility to place societal impact at the heart of our actions. Through a range of Giving-Back Programs, the company aims to make a positive difference in the communities where we operate.

This Movember, Ipsen once again champions men’s health through our “Get Men Talking” podcast series — a heartfelt initiative encouraging open conversations about prostate cancer and wellbeing.

Targeting what cannot be seen: Lindsey Rodrigues on the complexity of epigenetics or mutated in a particular cancer. We have to ask, ‘do we have an understanding of how this gene works? Can we design a medicine to treat it or to target it?”’

We’re proud to be part of The Liver Meeting 2025 hosted by the American Association for the Study of Liver Disease (AASLD), where leading healthcare professionals, scientists and the patient community come together to discuss the latest advances in scientific and medical innovations and care, across

Liver disease has emerged as a critical focus for the healthcare science community, driven by significant unmet needs—particularly in rare and underserved conditions.

Every person’s experience living with neuroendocrine tumors (NETs) is unique and for Melanie, coming to terms with a diagnosis of lung NETs is an ongoing journey, building knowledge and understanding of how to live with this complex and often unknown form of cancer.

Ipsen’s financial results for the first nine months of 2025 were published on 22 October 2025.

Hugo Gomes da Silva, SVP Global Medical Affairs (Rare Disease) at Ipsen, shares powerful insights into the evolving challenges families face throughout their PFIC journey—and highlights the critical importance of trusted information and community support.  

Nathan McCormack focuses on the earliest stages of active pharmaceutical ingredient (API) development.

Naomi Binoche, VP Head of Strategic Alliance Management, shares insights on how pharma partnerships are key to driving success and why celebrating every milestone along the way matters.

For the thousands of individuals, mostly women, living with primary biliary cholangitis (PBC), a chronic, progressive autoimmune liver disease, the journey can be lonely.

Lily May, a vibrant and determined seven-year-old, loves gymnastics and golf. Yet, like many children living with pediatric low-grade glioma (pLGG), her life has been profoundly shaped by this rare brain tumor. Although the global burden is unknown, pLGG is a rare childhood brain tumor.

Professor Björn Fischler, paediatric hepatologist at the Karolinska Institute in Sweden, and Laure Dorey, Director of the French patient organisation AMFE and mother of a child living with biliary atresia (BA), together discussed the realities of living with rare liver diseases (RLDs).

Fatigue is a distinct and debilitating condition that can have a significant impact on quality of life…

Ipsen’s Sandra Silvestri sat down with Dr. Laura Cristoferi, Professor Mark Swain, and Professor David Jones to explore the latest evidence on management of the rare, autoimmune disease, primary biliary cholangitis (PBC).

The first six months of 2025 have been exceptional for Ipsen. We’ve delivered strong growth across all three of our therapeutic areas — Rare Disease, Oncology, and Neuroscience — reflecting the strength of our strategy and the dedication of our teams. 

Joris is a thriving seven-and-a-half-year-old boy who has been on a journey requiring strength and hope from himself, and all those around him. At just four weeks old, Joris began exhibiting unusual symptoms; vomiting, changes in his eating habits and he had very pale poo.

Ipsen’s financial results for the first half of 2025 will be published on 31 July 2025 at 07:00 CET.

At just nine years old, Suzanne is a bright, creative young girl who loves dancing, drawing, exploring the woods, and watching birds. Despite living with Alagille syndrome (ALGS), a rare genetic condition, she embraces life with enthusiasm and curiosity.

A replay with complete presentation and Q&A session will be made available soon after the Annual General Meeting.

The financial results for the Full Year 2024 will be published on February 13, 2025 at 7H00 CET and a conference call will take place at 13H00 CET.

Cholestatic liver diseases are a rare but significant group of conditions that impact both children and adults. Three such conditions—Primary Biliary Cholangitis (PBC), Progressive Familial Intrahepatic Cholestasis (PFIC), and Alagille Syndrome (ALGS)—share commonalities yet are unique in their caus

In storytelling, you might hear of a superhero who squeezes coal with immense strength and heat, instantly creating a flawless diamond. While fiction, it’s true that diamonds are rare and formed under precise conditions over millions of years. For me, this analogy resonates deeply with the developme

In the latest installment of our ‘A Life in Science’ series, we’re excited to introduce Crystel Ogier, our Clinical Biomarker Director, who leads the awareness and implementation of companion diagnostics at Ipsen. Crystel’s work is a prime example of how cutting-edge science is making a real impact

Next in our ‘A Life in Science’ series, Dorinne Desposito, Predictive Toxicology Project Manager, shares her insights on driving innovation through creative thinking and the power of shared learning within our dedicated teams. Dorinne’s work exemplifies how cross-functional collaboration at Ipsen is

For individuals living with a rare disease, every day without treatment is a day too long. At the World Evidence, Pricing and Access (WEPA) congress in Amsterdam, I participated in a panel discussion on long-term access to rare disease innovation. The conversation reminded me that behind every polic

New in our ‘A Life in Science’ series, we hear from Christelle Huguet, Executive Vice President and Head of Research and Development, about what keeps her motivated in the challenging world of pharma.

Every day, millions of people around the world face the immense challenges of living with a rare disease. For these individuals and their families, resilience is essential, and hope becomes a lifeline. Rare Disease Day is a moment to honour their courage, amplify their voices, and reaffirm our share

An article by Josep Catlla, Executive Vice President, Chief Corporate Affairs Officer

Next on our ‘A Life in Science’ series, meet Sandra Silvestri, our Executive Vice President and Chief Medical Officer.

Ipsen is proud to launch our ‘A Life in Science’ campaign, spotlighting the talented and passionate individuals who are making their mark and driving innovation. 

Our performance in 2024 confirmed that our strategic initiatives are paying off, with significant advancements and robust financial growth across all three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Despite progress in gender equality, women remain underrepresented in STEM, making up just 1/3 of the workforce compared to 1/2 in non-STEM fields.1  

While being diagnosed with cancer isn’t unique- around 20m people are diagnosed with cancer globally each year, and that number is projected to double in next 20 years—how it affects each person is.

Watch our three-part vodcast series, Neuro Connections, developed in collaboration with the World Stroke Organization, where we discuss current post-stroke care challenges and potential solutions with global specialists, advocates and healthcare professionals.

Only 1 in 30,000 children are born with ALGS each year. This January, we are standing with the Alagille Syndrome Alliance to help raise awareness of this rare cholestatic liver disease and be #ALGSAware.

Ipsen’s Commercial Learning & Development programs are built on close collaboration between our global and local teams. Emily Birch, Brand Manager Oncology, UK; Kerstin Schoenherr, Training Manager, DACH; and Maxime Chesnais, Training Talent Management Director, France, share why cooperation and syn

How do you build best-in-class Commercial Learning & Development programs? We go behind the scenes with the experts: Guillermo Castillo Acero, Head of LATAM and General Manager of Brazil; Audrey Bergeron, Commercial Training Technology Manager, Global; and Marina D’Ascoli, Commercial Training Manage

With over 12 million people a year experiencing a stroke globally and over 100 million living with the effects and consequences of stroke, the burden of stroke is high and set to increase.

At Ipsen, we are proud to join the global initiative of International Anti-Corruption Day as part of our unwavering commitment to ethical practices and transparency. 

Biliary Atresia (BA) is a rare liver disease that usually appears in the first month of a baby’s life.1 In this disease, the bile ducts in the liver may not develop as expected, or become obstructed shortly after birth, causing…

For Bartek Bednarz, the healthcare industry is increasingly time-poor. “Medical technology evolves rapidly, pushing healthcare professionals (HCPs) to constantly adapt. Aging populations means HCPs are facing an influx of patients requiring complex, long-term care, while innovative healthcare delivery models, such…

When Ioana Parsons, General Manager of the UK & Ireland, thinks about continuous learning, she sees one part of a larger puzzle. “Business performance reflects overall organizational health,” she says. “Plenty of data shows that ‘healthy’ organizations perform better –…

As transformative medicines, advanced technologies and new methods change the way our field teams operate, healthcare professionals (HCPs) are facing a new paradigm. At Ipsen, our goal is to leverage our expertise to bring value to HCPs with the right information at the right time.

The results of our annual People Experience Survey are in and we’re proud of the progress we’ve made on our culture journey! More than 4,500 employees—approximately 86% of our workforce—shared their thoughts on what our culture is doing well and where we can do even better.

Ipsen’s Get Men Talking Podcast returns with a second episode for Movember 2024, continuing to urge men to get screened for prostate cancer and prioritise their long-term health. This year’s episode brings you a candid, heartfelt discussion with Tim Batchelor, now celebrating over 10 years cancer-fr

David Jenkins, SVP and Head of External Innovation and Research, leads efforts to identify, evaluate and secure new programs across Ipsen’s three strategic areas of Oncology, Rare disease, and Neuroscience. He shares his insights on the essential role that collaboration,…

Ipsen is proud to announce that 12 countries have been certified as a Great Place to Work in 2024. With that we are now considered as employer of choice in a total of 28 countries worldwide. This significant achievement reflects…

The United Nations Global Compact is a voluntary initiative that calls on CEOs worldwide to implement universal sustainability principles and support the United Nations (UN) goals. By joining the UN Global Compact, companies commit to aligning their strategies and operations with ten fundamental pri

The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.

Meeting the world’s highest standard for operational excellence is rare, and it’s even rarer to do it twice. Ipsen’s manufacturing site in Signes first received the Gold Shingo Prize for operational excellence in 2020.

Sustainability plays a critical role in shaping the future of our business and the world at large. To ensure we embed sustainability in our supply chain, we recently hosted our inaugural Supplier Sustainability Day event, bringing in key partners to meet with Ipsen leaders.  

A few months after Eva Luna was born, her mother Francesca realised something wasn’t quite right. Within the span of a few days, their world was turned upside down when her daughter was diagnosed with a rare liver disease, known as Progressive Familial Intrahepatic Cholestasis (PFIC). Yet despite th

We are proud to announce that Ipsen’s rating has reached an all-time high in the 2024 S&P Global Corporate Sustainability Assessment (CSA). Our score has increased by 4 points, from 57 in 2023 to 61 as od 19 September 2024, placing Ipsen in the 94th percentile of our industry. This remarkable achiev

Zero Emission Day is a global initiative that raises awareness about the impact of human activities on climate change and promotes sustainable practices. 

September is a month dedicated to raising awareness about Primary Biliary Cholangitis, I find myself reflecting on the challenges faced by those living with rare cholestatic disease. PBC Awareness Day on September 10th is not just a date on the calendar; it’s a reminder that understanding and suppor

At Ipsen, our commitment to supporting para-athletes is a direct reflection of our core values. We believe in removing barriers and fostering an environment where diversity is celebrated, and every individual is supported to drive innovation. Our company culture encourages all employees to reach the

It was only at 46 years old that Stephen was diagnosed with neuroendocrine cancer. Lovingly married to his wife and father to two sons freshly out of high school, in the prime of life with decades ahead of him, Stephen was shocked and confused by his diagnosis. His doctor told him he had 10 to 15 ye

“We’re often asked, what is the PBC journey? And the challenge is that, well, the PBC journey doesn’t exist. There are thousands and thousands of patients around the world, and each of them have an individual journey.” 

At Ipsen, our strategy is anchored in the principle of taking calculated risks to drive innovation. We inspire our employees to embrace innovation and approach risk-taking with a strategic mindset, ensuring that it aligns with our company’s objectives and ethical guidelines.

At Ipsen, our commitment to supporting para-athletes is deeply aligned with our core values of cultivating and embracing diversity. By standing alongside these incredible athletes, we demonstrate our dedication to fostering an inclusive environment where every individual is valued and encouraged to

The first six months of 2024 saw excellent sales growth of 9.5% at CER, and a core operating margin of 32.4%. In light of these strong results, we raised our 2024 total-sales guidance to over 7% growth, with a core operating margin of over 30%.

During the European Association for the Study of the Liver (EASL) congress, leading liver experts, Dr Mark Swain, Dr Emma Culver, and Dr Marco Carbone, sat down to discuss the effective management of primary biliary cholangitis (PBC)

The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.

The ESG Life Sciences Summit Europe, held in June brought together industry leaders to discuss how the life sciences sector can drive meaningful change through ESG initiatives. 

When Eric Gratton joined Ipsen from a large financial services firm, he was surprised to find there wasn’t an employee resource group (ERG) dedicated to the LGBTQIA+ community. “Being the over-achiever I am, I thought I should start one: a little passion project for the community and its allies.”

At the European Association for the Study of the Liver (EASL) congress, leading liver experts discuss the importance of proactive, personalized care and shared decision-making during consultations. A personalized care approach begins by listening to the patient’s feelings and needs, which can result

In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3,128 m.

Together for Kidney Cancer is a global disease awareness initiative funded by Ipsen aiming to raise awareness of the reality of people’s experiences living with kidney cancer and the importance of shared decision making to inform better care outcomes.

Biodiversity encompasses the rich array of species and ecosystems vital for our planet’s health. Yet, human activities have endangered this diversity, jeopardizing not only various species but also our daily lives. Biodiversity is crucial for human health, providing essential services such as pollin

Sandra Silvestri, Executive Vice President & Chief Medical Officer at Ipsen, reflects on the challenges women living with primary biliary cholangitis (PBC) face and why we have big dreams of a better future for PBC.

To mark World Clinical Trials Day, we sat down with Christelle Huguet, Executive Vice President, Head of R&D at Ipsen to explore the importance of diversity from all sides of the research and development process, as we accelerate innovation.  

Progressive Familial Intrahepatic Cholestasis (PFIC) is a rare liver disease that can pose significant challenges, particularly in young children1, but the good news is that there are growing opportunities to manage the disease, slow its progression and improve outcomes.  

A replay with complete presentation and Q&A session will be made available soon after the Annual General Meeting.

In March, we were proud to see Florence Dal Degan, Senior Director of External Innovation, participate in a panel discussion with different stakeholders, from consulting firms, pharma companies, investors to startups at BioEurope Spring entitled “Towards a Greener Globe: Biopharma’s Path to Sustaina

The Q1 2024 sales announcement will be published on April 24, 2024 at 7am CET. Find out more and register for the conference call for investors and analysts.

At seventy-one-years young, Gill, a devoted mother and grandmother from Nottinghamshire, loves spending time with her grandchildren and gardening. She also has a real passion for her volunteering work, to raise awareness of the ‘invisible, and isolating disease she has…

Sabrina is a lover of nature, mother and grandmother, whose outlook on life is to make every moment count. Sabrina lives with primary biliary cholangitis (PBC), which means every day is different depending on the severity of her symptoms, but…

We are pleased to share a recent conversation with Mary Jane Hinrichs, Senior Vice President, and Global Head of Early Development. Mary Jane spearheads the strategic direction and execution of early-stage programs at Ipsen, guiding them from drug candidate to…

As part of our commitment to accelerating transformative research and development, we’re excited to announce that our annual Golden Ticket competition is now open! Through our continued partnership with BioLabs, we’re delighted to be offering the brightest minds in biotech…

Ipsen’s Senior Director of Global Partnering for Oncology, Madee Gooriah, is part of the team leading efforts to expand Ipsen’s oncology franchise through external partnerships at every stage of development. But in an industry marked by complexity, how do we…

While 2023 saw us reach gender balance amongst the 170 top leaders of our organization, we know that our work towards the inclusion and empowerment of women doesn’t stop there. For International Women’s Day 2024, we’ve invited some of the…

Every four years, Rare Disease Day lands on the ‘rarest’ day of the year, 29th February. Due to leap years, this day is normally celebrated on 28th February, but this year means it is taking place on its intended day….

Hearing a rare liver disease diagnosis can be one of the most emotionally turbulent moments in a person’s life.1 For the parents of the estimated 1 in 50,000 – 100,000 newborns impacted by rare liver diseases, this moment is all…

11th February marks International Day of Women and Girls in Science. To celebrate the occasion, we spoke to Martine Zimmermann, Jill Buck, Alison Mason, Florence Meyer-Losic, and Christelle Huguet to hear the advice they would share with their younger selves…

Hear what Ipsen CEO David Loew has to say about our solid full-year results and a new era of dynamic growth.

Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.

Nora and her husband, Hector, met 39 years ago, got married shortly after, and have been inseparable ever since. In 2021, Hector was diagnosed with metastatic pancreatic cancer, which threw their entire family into navigating a very difficult diagnosis. Nora…

In 2023 Ipsen launched its third global patient organization engagement survey, featuring the perspectives of 85 patient organizations (POs) globally. These findings will be used to help Ipsen deliver on what matters most to patients and caregivers. For the third…

At the J.P. Morgan Healthcare Conference in San Francisco from January 8 to 11, 2024,  Ipsen’s management team leaders will discuss our transformation story, next phase of growth and external innovation ambitions.

At Ipsen, improving patients’ lives drives us. We work together with patients, for patients. However, we know that understanding how to be more patient centric can be challenging, especially if you don’t work with patients in your day-to-day role.

“The important thing with PBC is to take a holistic view of it, and think ‘What are the problems we are trying to solve? The first is the risk of progression to cirrhosis, and the other is symptoms and quality…

Starting now and throughout 2024, Ipsen is sponsoring five talented, elite athletes on their journeys toward the 2024 Paralympic Games.

Jennifer Schranz (Ipsen’s Global Head of Rare Diseases) attended The Liver Meeting from November 10-14, sharing key insights from her time onsite and explaining why scientific congresses are vital in helping advance innovation for patients. 

The outputs from the European Society of Medical Oncology (ESMO) Congress this year encompassed several important new data announcements, highlighting key advances in the development of therapies for people living with cancer.  However, cancer remains a formidable global health challenge,…

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation…

Ipsen plans to host a capital-markets day, starting at 12.30 pm GMT on 7 December 2023, at The Brewery, London. In-person attendance is by invitation only.

Developing innovation for people living with rare diseases is uniquely challenging. It requires all the different pieces of the puzzle– clinical viability, economic viability and the policy environment— to come together before innovation can reach patients.

At Ipsen we have been focused on developing new and innovative treatments for rare diseases for many years in endocrinology, rare bone disease and more recently in rare liver disease. This focus continues to be a core part of our…

Globally, stroke is the 2nd leading cause of death worldwide, in addition to being the 3rd leading cause of combined death and disability across the world, with approximately 1 in 4 people over the age of 25 expected to experience…

Stroke is the 2nd leading cause of death worldwide, in addition to being the 3rd leading cause of combined death and disability, with approximately 1 in 4 people over the age of 25 expected to experience a stroke at some point in their lives. 

At Ipsen we are incredibly proud of the way that our culture is evolving. Lived through our Ipsen Way of Being and supporting our business strategy, our team is demonstrating internally and externally our culture of collaboration and excellence and…

Ipsen has published its year to date and third-quarter sales results on 26 October 2023 at 7am CET.

At the latest edition of European Health Forum Gastein, Ipsen held an interactive session to raise awareness of the challenges inherent in drug development for rare and ultra-rare diseases. 

As anyone living with Primary Biliary Cholangitis (PBC) – a rare and progressive autoimmune liver disease1 – knows, the disease can have a significant impact on a person’s day to day life and relationships.2 

FOP is an ultra-rare genetic disorder where extra bone formation takes place in soft tissues, including muscles, tendons and ligaments, causing irreversible and progressive loss of mobility and leading to severe disability. To better understand the struggles that people living…

You can never truly understand what it’s like to live with an ultra-rare condition unless you’ve experienced it for yourself. With this in mind, we recently embarked on a project to help healthcare professionals experience what it’s like to live…

Primary biliary cholangitis (PBC) is a chronic autoimmune disease that affects liver function and can have debilitating symptoms for people living with the condition, including unrelenting itch, fatigue, pain and dry eyes and mouth. In addition, people who live with…

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder where extra bone formation takes place in soft tissues, including muscles, tendons and ligaments, causing irreversible and progressive loss of mobility, leading to severe disability. While the impact of the disease…

At Ipsen, we endeavor for all our clinical trials to be reflective of the real world, and this requires the participation of a cross-section of people living with a particular condition. However, for some stroke survivors with post-stroke spasticity –…

At Ipsen, we strive to improve the experiences of those participating in our clinical trials and do this by capturing insights from people living with the conditions we are investigating to help us to improve how we run our studies.  

We collaborated with Dystonia Europe to help uncover the unmet needs of people living with cervical dystonia – a rare, underdiagnosed neurological movement disorder that primarily affects the muscles in the neck. This can cause the head to turn to…

In France, we partnered with patient organization Association pour La Recherche sur les Tumeurs du Rein (A.R.T.u.R) and experts to help people living with kidney cancer overcome undernutrition.

We worked together with the Spanish patient organization NET España and local scientific society Grupo Español en Tumores Neuroendocrinos y Endocrinos (GETNE) on a podcast series to raise awareness of neuroendocrine tumors (NETs), a group of uncommon tumors that develop…

People living with prostate cancer in the Netherlands told us they needed more support around intimacy and sexual health due to the impact that their treatment can have on these. A LinkedIn poll also identified that 95% of caregivers of…

Despite evidence suggesting that involving people living with renal cell carcinoma (RCC) in treatment decisions can increase their overall survival and quality of life, there can be challenges to routinely embedding the Shared Decision Making (SDM) approach into practice.

At Ipsen, we are committed to helping people who are navigating the challenges of living with debilitating neurological conditions. This is why today, as we mark the start of the European Congress for Neurorehabilitation (ECNR) in Lyon, I want to…

2023 is off to a strong start. Hear how CEO David Loew would describe the last six months at Ipsen.

We are pleased to announce that Hemerion has been awarded Ipsen’s golden ticket 2023, receiving a year’s free lab space at the brand new, cutting-edge facility in the heart of Paris, France, close to Notre-Dame, at Paris Hôpital Hotel Dieu, AP-HP. 

Biolabs, a new biotech incubator located in the historic Hôtel Dieu, was inaugurated on 6 July 2023. As a founding sponsor of the initiative, Ipsen was represented at the event by CEO David Loew and Chief Business Officer Philippe Lopes…

“Symptom burden is the main issue for the patient.”– Professor Andreas Kremer, Hepatologist of the University of Zurich Hospital

“We are on the cusp of an absolute explosion in our approach to managing PBC.” – Professor Gideon Hirschfield, Hepatologist and Professor of Medicine at the University of Toronto. 

Experiencing any cancer diagnosis can be really overwhelming. However, prostate cancer can have its own nuances for those men who are living with it. John, from the UK, was diagnosed with prostate cancer in his mid-50s and he wants to…

Find out more about how we approach partnerships at Ipsen, where every program is a priority within our pipeline. We sat down with Zhen Su, CEO Marengo, to discuss our partnership and how we undertake a one team approach to…

2022 was a year of focus, momentum and growth at Ipsen. Learn about the progress we made and download the 2022 Integrated Annual Report here.

Diana was a full-time journalist when, at the age of 34, she experienced a stroke that impacted her movement and left her with spasticity.

Steve has been diagnosed with kidney cancer twice. After initial success with a nephrectomy, his cancer returned in January 2018. This time, his doctor said there was no treatment available. “He advised I would probably be put on life-extending drugs,”…

Collette spent almost 20 years going back and forth between different doctors and treatments, before she was finally diagnosed with PBC.

In September 2012, when she was 21, Caitlin received news every child dreads: her father had been diagnosed with pancreatic cancer and had been given three months to live.

The rare disease community continues to strive for innovative solutions to meet patient needs and ensure no person living with a rare disease is left behind.  

This year marks the 17th anniversary since the discovery of the ACVR1 gene was announced, a major scientific milestone in fibrodysplasia ossificans progressiva (FOP) research that helped us understand what causes the condition. On April 23, we marked FOP Awareness Day to honor…

Learn how to engage with our campaign and help protect your liver health. Every year, Liver Cancer Awareness Month (LCAM) is an opportunity to bring the sixth most prevalent cancer globally to the forefront of conversation, promoting awareness and the…

Hear what Ipsen CEO David Loew has to say about our strong full year and Q4 2022 results.

Ipsen leaders will attend the J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco, California. This event will bring together biotech companies, clinical researchers, investors and analysts from all over the world to learn about healthcare’s latest innovations.

‘Invisible’ diseases like primary biliary cholangitis (PBC) can be difficult to recognise, diagnose and to manage effectively. Here Prof. Gideon Hirschfield (University of Toronto, Departments of Medicine, Immunology and Medical Sciences) and Robert Mitchell-Thain, (PBC Foundation UK) discuss the disease,…

You can never truly understand what it’s like to live with an ultra-rare condition unless you’ve experienced it for yourself. And with this in mind, we recently embarked on a project to help healthcare professionals experience what it’s like to…

In December 2021, Ipsen received ISO 37001 certification for its anti-corruption management systems by Eurocompliance, a certification organization dedicated to the prevention of corruption. 

“Our growth platforms have delivered strong sales performance, reflecting improving commercial execution and the strength for our portfolio.” CEO David Loew

Ipsen announces that it becomes a founding sponsor of the second Biolabs innovation brain hub in Europe at Hopital Hotel Dieu, AP-HP, in Paris, France. The announcement builds on a 2018 commitment to a partnership with Biolabs for the development…

Continuing medical education is vital to maintaining the quality of clinical practice, which in turn can improve patient outcomes. As a pioneer in botulinum neurotoxin type A (BoNT-A) treatment, Ipsen has worked with a scientific steering committee of international experts…

I was honored to be invited to take on the challenge to live ‘A Life in a Day of a patient with FOP’ – but also apprehensive. The challenge simulated a day spent living as someone who has fibrodysplasia ossificans…

In October 2021, Ipsen pledged ambitious action on climate change. Today, we announce that Ipsen’s Climate Targets were approved by The Science Based Target initiative (SBTi). This approval confirms that our greenhouse gas (GHG) emission reduction target is in line…

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

The International Liver Congress (ILC)1 provides a key opportunity for us to meet and discuss the management and research of liver diseases. Given the online format of recent meetings, it was great to have the chance to interact, discuss and…

Hear what CEO David Loew has to say about our H1 2022 results.

PARIS, France, 29 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its resubmitted New Drug Application (NDA) for investigational palovarotene for the treatment of patients with…

By Steven Hildemann, MD, PhD, EVP, Chiel Medical Officer

Latest Update: March 29, 2022

Today, we are broadening our commitment to providing everyone with the opportunity to read and understand our research. From July 2022, we will publish, as a minimum, a 250-word plain language summary alongside all company-sponsored journal publications from human studiesa.

On the 15th of December 2021, Ipsen has been certified by Eurocompliance to the ISO 37001 standards for anti-corruption management systems.

PARIS, FRANCE, 20 December 2021 – 6:00 PM CET – Ipsen has learned that Cipla Limited and its subsidiary Cipla USA, Inc. has received final approval of a lanreotide product from the U.S. Food and Drug Administration; the FDA approval…

Today we are pleased to announce a partnership with the Queen’s University of Belfast (QUB), securing rights to a preclinical stage first-in-class FLIP inhibitor program, a cutting-edge drug discovery program which was supported by Wellcome. Commenting on this news Howard…

Today, we proudly stand together with more than 1000 companies worldwide who have pledged to tackle climate change and reduce greenhouse-gas (GHG) emissions as part of the Business Ambition for 1.5°C campaign, spearheaded by the United Nations and industry leaders.

Aujourd’hui, à l’occasion du congrès Reuters Events Pharma 2021, j’ai eu l’honneur d’échanger avec Izzy Gladstone sur les meilleures pratiques dans les affaires médicales et les bénéfices potentiels, pour les patients, d’une transformation axée sur le patient et le médecin.

By Steven Hildemann, MD, PhD, EVP, Chiel Medical Officer

For the first time in 2019, we made a big decision: to include Environmental, Social and Governance criteria when renegotiating the conditions of our external financing facility. By doing so, we committed to meeting specific targets.

We need to talk about how we’re feeling is the theme of World Kidney Cancer Day (WKCD) on 17 June 2021. To support this theme, Ipsen is launching Perspectives Matter; a social media campaign that brings to life the experiences and perspectives…

Ipsen’s Signes production site has received the Shingo (Gold) Award, the highest and most demanding distinction in operational excellence in the world.

We are delighted that this FOP Awareness Day Dr Rolf Morhart shared his invaluable insights gained through his career working in clinical practice supporting people living with the ultra-rare bone disease. Read his thoughts and reflections below.

PARIS, FRANCE, 8 March 2021 – Ipsen has learned that Amdipharm Ltd, which is believed to be a subsidiary of Advanz Pharma, has received a positive outcome by the Reference Member State, Denmark, and closure of the Decentralised Procedure, for…

We are pleased to announce the arrival of Gwenan White as Executive Vice President, Communications and Public Affairs, effective 1 March 2021. Based in Boulogne, France, she will be responsible for designing, implementing and managing the communications and public affairs…

Today is International Anti-Corruption Day. We are all aware that corruption has the potential to impact the social and economic development of all companies, societies and countries. That is why we must be unified in our efforts to conduct business…

Today, Ipsen is hosting a virtual Capital Markets Day to launch our new Group strategy which positions us for long-term success by focusing together for patients and society. Four priorities will drive continued growth and bring transformative medicines to patients….

David Loew, Chief Executive Officer, is pleased to host a Capital Markets Day webcast to present the Group’s Strategy on:

October is Liver Cancer Awareness Month and this year we are proud to be supporting the European Liver Patients Association (ELPA) with their campaign encouraging everyone to rethink liver cancer by bringing it to the forefront of conversations.

The facts and figures around breast cancer bring into focus the importance of raising awareness of the true scale of this globally prevalent disease. Breast cancer is the most common cancer in women1. It comprises of 24% of all cancers…

Innovation to improve patient outcomes doesn’t always resemble the scenes in the movies where the brilliant scientist makes a breakthrough alone in the lab. Sometimes it takes the form of Artificial Intelligence analyzing enormous quantities of data. Sometimes it looks…

We are pleased to announce the appointment of Bartek Bednarz, Executive Vice President Global Product & Portfolio Strategy and Patrice Zagame, Executive Vice President, Specialty Care International to the Executive Leadership Team (ELT), effective immediately.

We are delighted to welcome David Loew as the new CEO of Ipsen. A seasoned professional, David’s career has spanned nearly thirty years in the pharmaceutical industry in such companies as Roche and Sanofi. His leadership skills and experience in…